ZIOPHARM Oncology Inc. | Ownership
Companies that own ZIOPHARM Oncology Inc.
BlackRock Fund Advisors
8,431,136
5.92%
762,741
0%
06/30/2018
The Vanguard Group, Inc.
8,325,513
5.85%
143,067
0%
06/30/2018
SSgA Funds Management, Inc.
4,988,998
3.5%
-1,668,402
0%
06/30/2018
Miller Value Partners LLC
4,916,671
3.45%
-121,275
0.48%
06/30/2018
MSD Partners LP
3,410,500
2.4%
0
0.25%
06/30/2018
Northern Trust Investments, Inc.
1,632,612
1.14%
52,220
0%
06/30/2018
Geode Capital Management LLC
1,351,949
0.95%
164,983
0%
06/30/2018
Morgan Stanley Smith Barney LLC (Private Banking)
889,074
0.62%
-86,581
0%
06/30/2018
Norges Bank Investment Management
818,864
0.56%
-219,664
0%
12/31/2017
Susquehanna Financial Group LLLP
780,678
0.55%
-135,845
0.01%
06/30/2018
| Address |
Parris Building
Boston Massachusetts 02129
United States
|
|
Employees
|
- |
| Website |
http://www.ziopharm.com |
| Updated |
07/08/2019 |
| ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of a diverse portfolio of cancer therapies. It focuses on developing products in immuno-oncology that employ novel gene expression, control, and cell technologies for the treatment of cancer. The company was founded on September 9, 2003 and is headquartered in Boston, MA. |
